Drug details

Eylea (aflibercept)

type of Macular Degeneration Agents, Ophthalmics, VEGF Inhibitors

Eylea (aflibercept) is a recombinate protein indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD). AMD is a common cause of blindness.

This drug may have the following side effects:

• chest pain,
• confusion, and
• sudden numbness or weakness (especially on one side of the body),
• seeing halos around lights,
• swelling around your eyes,
• problems with speech or balance
• sudden vision problems,
• eye pain or redness,
• increased sensitivity of your eyes to light,
• seeing flashes of light or "floaters" in your vision,
• sudden severe headaches,

The following drugs are related to Eylea, either as a replacement or used together:

• Eylea HD (aflibercept injection)
• Beovu (brolucizumab-dbll for intravitreal injection)
• Byooviz (ranibizumab-nuna injection, for intravitreal use)
• Cimerli (ranibizumab-eqrn injection)
• Vabysmo (faricimab-svoa injection)
• Syfovre (pegcetacoplan injection, for intravitreal use)
• Susvimo (ranibizumab injection)
• Xipere (triamcinolone acetonide injectable suspension)
• Visudyne (verteporfin injection)